FORE-8394 is an investigational, novel, small-molecule, next-generation, orally available selective inhibitor of mutated BRAF. Its broad inhibition of ERK signaling makes it a strong candidate for the treatment of tumors driven by class I or II BRAF mutants and fusions.
Tutuka, C.S.A., Andrews, M.C., Mariadason, J.M. et al. “PLX8394, a new generation BRAF inhibitor, selectively inhibits BRAF in colonic adenocarcinoma cells and prevents paradoxical MAPK pathway activation”. Mol Cancer 16, 112 (2017).
Okimoto, Ross A., et al. “Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer.” Proceedings of the National Academy of Sciences 113.47 (2016): 13456-13461.
Yao, Zhan, et al. “RAF inhibitor PLX8394 selectively disrupts BRAF dimers and RAS-independent BRAF-mutant-driven signaling.” Nature medicine 25.2 (2019): 284-291.
Zhang, Chao, et al. “RAF inhibitors that evade paradoxical MAPK pathway activation.” Nature 526.7574 (2015): 583-586.
Hartsough, Edward J., et al. “Response and resistance to paradox-breaking BRAF inhibitor in melanomas in vivo and ex vivo.” Molecular cancer therapeutics 17.1 (2018): 84-95
Yao, Zhan, et al. “Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.” Nature 548.7666 (2017): 234-238.
Janku, F., et al. “Interim results from a phase 1/2 precision medicine study of PLX8394-a next generation BRAF inhibitor.” European Journal of Cancer 138 (2020): S2-S3.